Vertex Minerals (ASX:VTX) has processed first ore and begun commissioning of the high-grade Reward gold mine, with sales ...
Along with its gene editing therapy Casgevy, Vertex is offering fertility preservation support for its patients—a program ...
HHS challenges Vertex Pharmaceuticals' fertility services program, alleging violations of anti-kickback laws linked to its ...
The S&P 500’s health care sector (NYSEARCA:XLV), holding a weightage of 12.12% in the S&P 500 index, saw a fall of 10.2% in ...
Vertex Pharmaceuticals Inc. closed 18.39% short of its 52-week high of $519.88, which the company reached on November 8th.
Vertex is paying Orna $65 million upfront, in part via convertible note, according to a Jan. 7 release. Orna—which acquired ...
Analyst Evan Seigerman of BMO Capital maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report), retaining the price target of ...
On Sunday, Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) announced multiple program updates, including: In December, the FDA approved Vertex's Alyftrek (vanzacaftor / tezacaftor ...
CRISPR stock decline is influenced by Editas Medicine's struggles, but CRSP remains strong with FDA approval and strategic ...
Morgan Stanley analyst Terence Flynn maintained a Hold rating on Vertex Pharmaceuticals (VRTX – Research Report) today and set a price target ...
Vertex Minerals (ASX:VTX) is on track to sell first gold from its Reward Gold Mine in the Eastern Lachlan Fold Belt of ...